AFMK|cas:52450-38-1|西域试剂

AFMK,99.77%

产品编号：Bellancom-113314| CAS NO：52450-38-1| 分子式：C₁₃H₁₆N₂O₄| 分子量：264.28

AFMK是褪黑素的抗氧化代谢产物，可减轻X射线对小鼠DNA、蛋白质和脂质的氧化损伤。AFMK是一种较差的清道夫。AFMK在生理pH下的pKa为8.7。抗氧化能力。AFMK通过调节凋亡途径提高吉西他滨在PANC-1细胞中的抗肿瘤作用。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-113314	￥750.00	杭州北京（现货）
Bellancom-113314	￥2250.00	杭州北京（现货）
Bellancom-113314	￥3600.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

AFMK

产品介绍

AFMK 是褪黑激素的一种抗氧化代谢物，可减弱 X 射线诱导的小鼠 DNA、蛋白质和脂质氧化损伤。AFMK 是效果稍低的一种清洁剂，在生理 pH 值下的 pK_a 为 8.7。具有抗氧化活性。AFMK 可通过调节细胞凋亡途径提高 Gemcitabine 在 PANC-1 细胞中的抗肿瘤作用。

生物活性

AFMK, antioxidant metabolite of Melatonin, attenuates X-ray-induced oxidative damage to DNA, proteins and lipids in mice. AFMK is a poorer scavenger. The pK_a of AFMK at physiological pH is 8.7. Antioxidant capacity. AFMK improves the anti-tumor effect of Gemcitabine in PANC-1 cells through the modulation of apoptotic pathway.

体外研究

AFMK is one of the metabolites of melatonin and can be formed by both enzymatic or pseudoenzymatic and nonenzymatic metabolic pathways.
AFMK pretreatment significantly inhibits DNA damage. AFMK shows a very high level of in vitro hydroxyl radical scavenging potential which was measured by an electron spin resonance (ESR) study. IC₅₀ values resulting from ESR analysis was 338.08 nM. AFMK, a melatonin metabolite, is a sparingly investigated biogenic amine.
AFMK administered to PANC-1 in combination with Gemcitabine inhibits the production of HSP70 and cIAP-2 as compared to the results obtained with Gemcitabine alone.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	Human pancreatic carcinoma cell line (PANC-1)
Concentration:	0.001, 0.1, 10, 1000 nM
Incubation Time:
Result:	Augmented the inhibitory effects on HSP70 expression from 0.47 (Gemcitabine alone) to 0.13 (10 nM AFMK), 0.08 (0.1 nM AFMK) and 0.01 (0.001 nM AFMK).

体内研究
(In Vivo)

AFMK is a potent antioxidant in vivo. AFMK significantly reverses radiation-induced decline in the total antioxidant capacity of plasma in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL mice 8 wk of age
Dosage:	10 mg/kg body weight
Administration:	Intraperitoneal injection
Result:	Radiation-induced decline in the total antioxidant capacity of plasma was significantly reversed in AFMK pretreated mice. AFMK-pretreated irradiated groups showed a significantly lower value of comet tail length and % DNA in tail.

体内研究

AFMK is a potent antioxidant in vivo. AFMK significantly reverses radiation-induced decline in the total antioxidant capacity of plasma in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL mice 8 wk of age
Dosage:	10 mg/kg body weight
Administration:	Intraperitoneal injection
Result:	Radiation-induced decline in the total antioxidant capacity of plasma was significantly reversed in AFMK pretreated mice. AFMK-pretreated irradiated groups showed a significantly lower value of comet tail length and % DNA in tail.

体内研究

AFMK is a potent antioxidant in vivo. AFMK significantly reverses radiation-induced decline in the total antioxidant capacity of plasma in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL mice 8 wk of age
Dosage:	10 mg/kg body weight
Administration:	Intraperitoneal injection
Result:	Radiation-induced decline in the total antioxidant capacity of plasma was significantly reversed in AFMK pretreated mice. AFMK-pretreated irradiated groups showed a significantly lower value of comet tail length and % DNA in tail.

性状

Solid

溶解性数据

In Vitro:

DMSO : 50 mg/mL (189.19 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.7839 mL	18.9193 mL	37.8387 mL
5 mM	0.7568 mL	3.7839 mL	7.5677 mL
10 mM	0.3784 mL	1.8919 mL	3.7839 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (9.46 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (9.46 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (9.46 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (9.46 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (9.46 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (9.46 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。